Bezisterim Phase 2 Trial for New Patients Set to Launch

BioVie is set to begin a Phase 2 clinical trial of bezisterim, an oral treatment for newly diagnosed Parkinson's disease patients, in early 2025. The trial, named SUNRISE-PD, will assess bezisterim as a first-line, stand-alone therapy aimed at reducing neuroinflammation and improving insulin sensitivity. The study will involve up to 60 participants and is funded with over $15 million. Bezisterim has shown promise in reducing both motor and nonmotor symptoms in previous trials.